Protocol for a multicenter observational prospective study of functional recovery from stroke beyond inpatient rehabilitation - The Interdisciplinary Platform for Rehabilitation Research and Innovative Care of Stroke Patients (IMPROVE).
Disability and health
Functional recovery
Hand motor function
International classification of functioning
Rehabilitation
Stroke
Journal
Neurological research and practice
ISSN: 2524-3489
Titre abrégé: Neurol Res Pract
Pays: England
ID NLM: 101767802
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
02
2020
accepted:
11
03
2020
entrez:
16
12
2020
pubmed:
17
12
2020
medline:
17
12
2020
Statut:
epublish
Résumé
Stroke and its long-term consequences pose major challenges for the lives of those affected and healthcare systems. Neurological rehabilitation therefore primarily attempts to improve function in order to increase independence in activities of daily living, and to enable social participation. There is only scarce data on dynamics of functional recovery after patients discharge from inpatient neurological rehabilitation. Even less is known about the patient's perspective on long-term recovery from stroke. The Interdisciplinary Platform for Rehabilitation Research and Innovative Care of Stroke Patients (IMPROVE) aims to address this knowledge gap by providing new insights into the dynamics and extent of functional recovery from stroke beyond inpatient rehabilitation treatment. We provide the protocol for an observational, longitudinal, multicenter study conducted in an Universitary Stroke Center in cooperation with five Neurological Rehabilitation Centers in Northern Germany. Patients who suffered from ischemic or hemorrhagic stroke will be enrolled by the end of inpatient rehabilitation and followed up to 1 year. In addition, a group of chronic stroke patients and a group of craniocerebral trauma patients will be enrolled as a comparison group. Data on stroke characteristics, vascular risk factors, co-morbidities, social support, and demographics will be recorded. Comprehensive clinical evaluation will be performed at baseline, three, six, and twelve months after enrollment. The assessments and scores used reflect the three components of the International Classification of Functioning, Disability and Health (ICF), some of them are tests regularly used in rehabilitation settings. Tests of motor function, cognition, and mood are included, as are tests of self-reported health-related quality of life. Primary outcome measure is a hand motor score, built by the sum of the hand items of the Fugl-Meyer Assessment as an objective measurement of hand function at 12 months after enrollment. Predictors of the primary outcome will be analyzed using linear regression analysis. The results of IMPROVE will inform about the long-term dynamics of functional stroke recovery after patients' discharge from inpatient rehabilitation and will provide insights into the association of clinical and demographic factors with recovery of function. The protocol is registered at ClinicalTrials.gov (NCT04119479).
Identifiants
pubmed: 33324916
doi: 10.1186/s42466-020-00056-2
pii: 56
pmc: PMC7650143
doi:
Banques de données
ClinicalTrials.gov
['NCT04119479']
Types de publication
Clinical Trial
Langues
eng
Pagination
10Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsGBi, SW, TI, CB, Gbe, AM, AN, KO, OP, MP, JS have no conflict of interest. CG reports personal fees from Amgen, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi Aventis, Abbott, and Prediction Biosciences outside the submitted work. GT reports receiving consulting fees from Acandis, grant support, and lecture fees from Bayer, lecture fees from Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo, and consulting fees and lecture fees from Stryker outside the submitted work.
Références
Clin Med (Lond). 2015 Oct;15(5):461-4
pubmed: 26430186
Stroke. 2017 Jul;48(7):1818-1826
pubmed: 28526765
Mult Scler. 2009 Dec;15(12):1509-17
pubmed: 19995840
Scott Med J. 1957 May;2(5):200-15
pubmed: 13432835
Psychosomatics. 2009 Nov-Dec;50(6):613-21
pubmed: 19996233
Int J Stroke. 2014 Apr;9(3):313-20
pubmed: 23227818
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Stroke. 2016 Feb;47(2):539-41
pubmed: 26732564
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Circulation. 2014 Jan 21;129(3):e28-e292
pubmed: 24352519
Stroke. 2010 May;41(5):1048-50
pubmed: 20224060
Restor Neurol Neurosci. 2006;24(4-6):273-85
pubmed: 17119304
J Phys Ther Sci. 2015 Jun;27(6):1665-70
pubmed: 26180294
Stroke. 2016 Jan;47(1):180-6
pubmed: 26604251
Nicotine Tob Res. 2012 Jan;14(1):75-8
pubmed: 22025545
Md State Med J. 1965 Feb;14:61-5
pubmed: 14258950
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
Eur J Prev Cardiol. 2019 Jul;26(11):1150-1157
pubmed: 30955367
Neurorehabil Neural Repair. 2017 Oct-Nov;31(10-11):864-876
pubmed: 29233071
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
Arch Phys Med Rehabil. 2014 Apr;95(4):595-6
pubmed: 24529594
Rehabilitation (Stuttg). 1995 May;34(2):69-73
pubmed: 7624593
Qual Life Res. 2013 Sep;22(7):1717-27
pubmed: 23184421
J Neurol Neurosurg Psychiatry. 2002 Aug;73(2):160-6
pubmed: 12122175
Lancet Glob Health. 2013 Nov;1(5):e259-81
pubmed: 25104492
Lancet Neurol. 2009 Aug;8(8):741-54
pubmed: 19608100
F1000Res. 2016 Jun 22;5:
pubmed: 27408689
Eur J Neurol. 2010 Jan;17(1):59-66
pubmed: 19614961
Scand J Rehabil Med. 1975;7(1):13-31
pubmed: 1135616
Int J Stroke. 2016 Jun;11(4):454-8
pubmed: 27073187
BMC Health Serv Res. 2018 Jun 19;18(1):468
pubmed: 29914476
Dtsch Arztebl Int. 2008 Jun;105(26):467-73
pubmed: 19626195
Stroke. 1989 Jul;20(7):864-70
pubmed: 2749846
Stroke. 1999 Oct;30(10):2131-40
pubmed: 10512918